AIM ImmunoTech News - September 1, 2026

🟢 AIM ImmunoTech is trading 5.8% up today after announcing broad Ampligen-pembrolizumab patent

AIM ImmunoTech is trading 5.8% up now at $0.24 after announcing a broad U.S. patent covering Ampligen combined with pembrolizumab for cancer treatment. - The...

🟢 AIM ImmunoTech is trading 17.52% up in pre-market after broad U.S. patent covering Ampligen and pembrolizumab

AIM ImmunoTech is trading at $0.27, up 17.52% in pre-market trading on September 1, 2026, after announcing a broad U.S. patent for Ampligen combined with...